Literature DB >> 18163954

Phenotypic and functional analysis of LCMV gp33-41-specific CD8 T cells elicited by multiple peptide immunization in mice revealed the up-regulation of PD-1 expression on antigen-specific CD8 T cells.

Yi Liu1, Lihui Xu, Yiqun Jiang, Jianfang Sun, Xianhui He.   

Abstract

The phenotype and function of antigen-specific CD8 T cells are closely associated with the efficacy of a therapeutic vaccination. Here we showed that multiple immunizations with LCMV gp33-41 peptide (KAV) in Freund's adjuvant could induce KAV-specific CD8 T cells with low expression of CD127 and CD62L molecules. The inhibitory receptor PD-1 was also expressed on a substantial part of KAV-specific CD8 T cells, and its expression level on KAV-specific CD8 T cells in spleen and lymph nodes was much higher when compared to those in peripheral blood. Furthermore, KAV-specific CD8 T cells could specifically kill KAV-pulsed target cells in vivo but the efficiency was low. These data suggest that prime-boost vaccination schedule with peptide in Freund's adjuvant can elicit antigen-specific CD8 T cells of effector-like phenotype with partial functional exhaustion, which may only provide short-term protection against the pathogen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18163954

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  2 in total

1.  Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.

Authors:  Christelle Remy-Ziller; Claire Germain; Anita Spindler; Chantal Hoffmann; Nathalie Silvestre; Ronald Rooke; Jean-Yves Bonnefoy; Xavier Préville
Journal:  Clin Vaccine Immunol       Date:  2013-12-04

2.  High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment.

Authors:  Victoria A Brentville; Rachael L Metheringham; Barbara Gunn; Lindy G Durrant
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.